Patient-derived organotypic tissue cultures as a platform to evaluate metabolic reprogramming in breast cancer patients
Data files
Apr 21, 2025 version files 38.96 MB
-
Archive.zip
38.96 MB
-
README.md
6.70 KB
Abstract
Five patient-derived organotypic cultures from patients with treatment-naïve primary ER+/PR+/HER2- tumors while one came from a patient with neoadjuvant therapy for locally metastatic ERlow/PR-/HER2- tumor. They all exhibited tissue outgrowth in one month with some CA OTC harboring isolatable organoids and fibroblasts. We interrogated reprogrammed metabolism in CA versus paired NC OTC with dual 2H7-glucose/13C5,15N2-Gln tracers coupled with Stable Isotope-Resolved Metabolomic analysis. The data are provided as Excel spreadsheets for each patient. The entries comprise reduced data from FT-MS analyses in terms of identified compounds, their ion intensities for each isotopologue, injection volumes and derived normalized concentrations. These data can therefore be reanalyzed as desired.
Dataset DOI: 10.5061/dryad.4qrfj6qnm
Description of the data and file structure
Five patient-derived organotypic cultures from patients with treatment-naïve primary ER+/PR+/HER2- tumors while one came from a patient with neoadjuvant therapy for locally metastatic ERlow/PR-/HER2- tumor. They all exhibited tissue outgrowth in one month with some CA OTC harboring isolatable organoids and fibroblasts. We interrogated reprogrammed metabolism in CA versus paired NC OTC with dual 2H7-glucose/13C5,15N2-Gln tracers coupled with Stable Isotope-Resolved Metabolomic analysis. The data are provided as Excel spreadsheets for each patient. The entries comprise reduced data from FT-MS analyses in terms of identified compounds, their ion intensities for each isotopologue, injection volumes and derived normalized concentrations. These data can therefore be reanalyzed as desired.
Files and variables
1. File: CZ16_17.xlsx.zip
Description: Reduced FT MS data for OTCs from patients 16 & 17
2. File: CZ19.xlsx.zip
Description: Reduced FT MS data for OTCs from patient 19
3. File: CZ20.xlsx.zip
Description: Reduced FT MS data for OTCs from patient 20
4. File: CZ21.xlsx.zip
Description: Reduced FT MS data for OTCs from patient 21
5. File: CZ22.xlsx.zip
Description: Reduced FT MS data for OTCs from patient 22
Note: All files have the same column structure.
Column Definitions (in .xlsx files)
- Inf = infinity: divide by zero in the normalization
- NA = not available
| Column | Name | Description |
|---|---|---|
| A | Compound | Compound name |
| B | Mol_Formula | Molecular formula |
| C | C_isomers | Number of 13C atoms present |
| D | N_isomers | Number of 15N atoms |
| E | H_isomers | Number of 2H (D) atoms |
| F | CND | Isotopologue descriptor (summary of columns C–E) |
| G | SamplID | File name containing tissue type |
| H | Intensity | Ion intensity: Raw peak area as ion counts |
| I | Original.Intensity | Original ion intensity. Same as column H |
| J | Corrected.Intensity | Corrected ion intensity from column H |
| K | Flags | Ignore: Comment on whether ion was detected (not needed for analysis) |
| L | Peak-Index | Peak number in mass spectrum |
| M | Quantified_uM_ratio | Quantification in µM |
| N | Quantified_uM_sequence_ratio | Sequenced quantification in µM |
| O | reconstitution_volume_uL | Volume of reconstituted sample (µL) |
| P | injection_volume_uL | Volume injected (µL) |
| Q | protein_mg | Protein quantity in sample extracted (mg) |
| R | icms_split_ratio | Fraction of total sample analyzed by IC-FTMS |
| S | Amount_ProteinAdj_uMol_g_protein_RatioBased | Analyte amount normalized to protein (µmol/g), ratio-based |
| T | Amount_ProteinAdj_uMol_g_protein_SequenceBased | Analyte amount normalized to protein (µmol/g), sequence-based |
| U | CommentQuantification | Comments |
| V | Fraction | Mole fraction of ion |
| W | Normalized_intensity | Corrected peak intensity normalized to protein |
Code/software
Microsoft Excel: Apart from natural abundance corrections, all calculations can be performed within Excel.
Access information
Data was derived from the following sources:
IC-UHR-FTMS was performed following published procedure. Briefly, metabolites were separated on a Thermo Scientific Dionex™ IonPac AG11-HC analytical column paired with a Dionex IonPac AS11-HC guard column in a Dionex ICS-5000+ DP Ion Chromatography system. Eluted metabolites were detected by a Thermo Fisher Orbitrap Fusion™ Tribrid™ mass spectrometer (Waltham, MA, USA) run in both negative MS1 and MS/MS (Data-Independent Analysis or DIA) modes. The MS1 scan was acquired with a resolving power of 500,000 at m/z 200 and an m/z range of 80 to 800, while the DIA scan was obtained with a resolution of 60,000 and a precursor m/z range of 280–440 with a wide isolation window of 200 m/z. TraceFinder™ software and an in-house database were used for data analysis. MS1 peak areas of assigned metabolites and isotopologues were corrected for natural abundance and quantified against a calibration standard mixture. Metabolite amounts thus obtained were normalized by dry residue weight.
Human subjects data
Ethics Approval and Consent to Participate
All patients were consented prior to surgery for their tissue collection under the approved protocol of the University of Kentucky Institutional Review Board (IRB#44224, Total Cancer Care). The studies in this work abide by the Declaration of Helsinki principles.
Dual stable isotope tracer treatment
Each patient’s OTC was replaced with a stable isotope tracer medium 2-3 weeks after culturing in BCOM. The tracer medium was composed of 0.68% (w/v) D7 (2H7)-glucose + 7.44 mM 13C5,15N2-Gln in BCOM and the treatment lasted for 2 (CZ016-017) or 3 days (CZ019-022). At tissue harvest, two small pieces of CZ016-017 OTC were cut for histology and live fluorescence spectroscopy while the rest were metabolically quenched in liquid N2 before further processing for SIRM analysis. The CZ019-022 OTC were processed similarly for histology and SIRM analysis.
Tissue and medium extraction
Frozen OTC were pulverized into 10 µm particles in liquid N2 with a SPEX 6775 Freezer/Mill (SPEX SamplePrep, Metuchen, NJ) to maximize metabolite extraction. Polar/non-polar metabolites and proteins were extracted simultaneously using the acetonitrile:H2O:chloroform (2:1.5:1, v/v) solvent partitioning method as described previously (16). Polar metabolite extracts were split and lyophilized for NMR and IC-UHRFTMS analysis described below. For medium extraction, a 50 µL aliquot was mixed with 200 µl cold acetone (-20°C) (80% acetone final) and kept at -80°C for 20-30 min before centrifugation at 21,100xg for 20 min at 4°C to remove protein precipitates. The extracts were lyophilized before NMR analysis.
Stable Isotope-Resolved Metabolomic (SIRM) analysis
Lyophilized polar extracts were dissolved in H2O for anionic ion chromatography coupled with ultra high-resolution Fourier transform mass spectrometric (IC-UHRFTMS) analysis. The D, 13C, and/or 15N labeling patterns (total abundance in µmole/g residue and fractional enrichment) of relevant metabolites were used to reconstruct various catabolic and anabolic pathways.
Isotopologue nomenclature
As three stable isotopes were used, the number of transformed isotopologues was too large and unnecessary to display individually. For example, Asp with four 13C, three 15N, and one D (C4N3D) may have up to 5*2*4=40 isotopologues. We thus summed up relevant isotopologues for each metabolite for meaningful interpretation. For example, C3Dx is the sum of isotopologues having three 13C atoms and any number of D, whereas C*Dx is the sum of isotopologues with ≥ one 13C and any number of D. Total* is the sum of all labeled isotopologues observed. The unlabeled isotopologue is C0N0D0, i.e., no 13C, 15N, or D.
